Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16455
Full metadata record
DC FieldValueLanguage
dc.contributor.authorReid, Christopher A-
dc.contributor.authorHildebrand, Michael S-
dc.contributor.authorMullen, Saul A-
dc.contributor.authorHildebrand, Joanne M-
dc.contributor.authorBerkovic, Samuel F-
dc.contributor.authorPetrou, Steven-
dc.date2016-10-23-
dc.date.accessioned2016-12-07T01:57:08Z-
dc.date.available2016-12-07T01:57:08Z-
dc.date.issued2017-01-
dc.identifier.citationBritish Journal of Pharmacology 2017; 174(2): 119-125en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16455-
dc.description.abstractZn2+ , the second most prevalent trace element in the body, is essential for supporting a wide range of biological functions. While the majority of Zn2+ in the brain is protein-bound, a significant proportion of free Zn2+ is found co-localized with glutamate in synaptic vesicles and is released in an activity-dependent manner. Clinical studies have shown Zn2+ levels are significantly lower in blood and cerebrospinal fluid of children that suffer febrile seizures. Likewise, investigations in multiple animal models demonstrate that low levels of brain Zn2+ increase seizure susceptibility. Recent work provides human genetic evidence that disruption of brain Zn2+ homeostasis at the level of the synapse is associated with increased seizure susceptibility. In this review we will explore the clinical, functional and genetic data supporting the view that low synaptic Zn2+ increases cellular excitability and febrile seizure susceptibility. Finally, the review will focus on the potential of therapeutic Zn2+ supplementation for at risk patients.en_US
dc.subjectZn2+en_US
dc.subjectDieten_US
dc.subjectFebrile seizuresen_US
dc.subjectFeveren_US
dc.subjectInflammationen_US
dc.subjectSynapticen_US
dc.subjectZincen_US
dc.titleSynaptic Zn2+ and febrile seizure susceptibilityen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleBritish Journal of Pharmacologyen_US
dc.identifier.affiliationThe Florey Institute for Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationEpilepsy Research Centre, Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationCell Signalling and Cell Death Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medical Biology, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27771943en_US
dc.identifier.doi10.1111/bph.13658en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-4580-841Xen_US
dc.type.austinJournal Articleen_US
local.name.researcherBerkovic, Samuel F
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

38
checked on Oct 1, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.